Providers

Patients aged 30 to 40 years with type 1 diabetes had the highest risk of sudden cardiac death, according to 2010 data from Denmark.

The guidelines highlight the need for lifelong obesity management, early diagnosis, comorbidity prevention, and patient-centered care.

McKesson's report highlights key trends in community oncology, emphasizing patient-centered care, precision medicine, and the need for innovative clinical trials.

Within the same physician groups, 2-sided risk in Medicare Advantage (MA) was associated with higher quality and lower utilization for dually eligible beneficiaries compared with fee-for-service MA and traditional Medicare.

Phase 3 OCEANIC-STROKE data show how asundexian offers a potential new secondary stroke prevention option.

Long-term data suggest stress echocardiography can uncover impaired exercise capacity and predict worse outcomes in patients.

After 8 months of treatment with mavacamten, 5% of patients developed new atrial fibrillation or flutter and 4% developed heart failure.

The expansion of direct-to-consumer (DTC) pharmaceutical manufacturer models and the upcoming TrumpRx launch offer lower costs but create new complexities for patients.

A case-crossover study found that extreme heat increased mortality between 10% and 18%, with higher risks in vulnerable groups.

Svetlana Barbarash, MD, outlines the lack of cardiologists and transplant services in Las Vegas and the policy changes needed to close gender gaps in care.

Onasemnogene abeparvovec-brve is now the first gene replacement therapy approved for spinal muscular atrophy in patients 2 years and older.

Svetlana Barbarash, MD, explains how better education, digital monitoring tools, and coordinated care can improve arrhythmia detection and outcomes.

Chimeric antigen receptor T-cell therapies, along with bispecific antibodies, have changed the treatment paradigm for patients with relapsed or refractory mantle cell lymphoma.

A new analysis based on two prospective trials helps clarify the roles of chemotherapy and radiotherapy.

Resmetirom improved MASH and fibrosis consistently across patients regardless of GLP-1 or SGLT2 inhibitor use, with outcomes further enhanced in those who achieved at least 5% weight loss.

Chronic kidney disease now affects more than 788 million adults globally, with rising prevalence, increasing mortality, and substantial contributions to cardiovascular deaths

A study identified 32 dysregulated cytokines and 5 key signaling hubs in idiopathic pulmonary fibrosis (IPF), mapping a complex network of profibrotic pathways that may serve as future therapeutic targets.

A combined assessment of genetic, serologic, and clinical factors may enhance early recognition of patients with RA who are most at risk for ILD.

Modern ibrutinib-based approaches substantially narrow the traditional survival gap observed in CLL.

Baricitinib demonstrated significant reductions in disease activity in postmenopausal women with frontal fibrosing alopecia over 12 weeks.

Remibrutinib demonstrated rapid and sustained symptom relief for chronic spontaneous urticaria in a pooled analysis of REMIX-1 and REMIX-2.

Urticaria symptom reduction with remibrutinib was linked with improved quality of life and sleep for patients with chronic spontaneous urticaria.

Research shows a sharp rise in bisphenol-attributable metabolic disease since 2000, with annual costs exceeding $250 billion in North America.

Remibrutinib shows rapid and sustained relief for chronic spontaneous urticaria, offering a promising oral treatment option for patients.

Caregivers face communication challenges in coordinating patient care for older adults, highlighting the need for improved support and training.